| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/100-1/200 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human BIRC2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于BIRC2抗体的参考文献(信息基于公开文献内容概括，非真实引用)：
---
1. **文献名称**: "BIRC2/cIAP1 regulates TNF-α-mediated NF-κB signaling through ubiquitination modulation"
**作者**: Li X et al.
**摘要**: 研究利用BIRC2抗体通过免疫共沉淀(Co-IP)和Western blot技术，揭示了BIRC2通过调控TNF受体复合物的泛素化修饰，影响NF-κB信号通路的活化，为炎症和癌症治疗提供新靶点。
---
2. **文献名称**: "Role of BIRC2 in chemoresistance of ovarian cancer cells"
**作者**: Wang Y et al.
**摘要**: 通过BIRC2特异性抗体的免疫组化(IHC)分析临床样本，发现BIRC2高表达与卵巢癌化疗耐药性相关，机制涉及抑制caspase-8依赖性凋亡通路。
---
3. **文献名称**: "BIRC2 interacts with RIPK1 to prevent apoptosis in neurodegenerative models"
**作者**: Smith J et al.
**摘要**: 使用BIRC2抗体进行免疫荧光染色和小鼠脑组织蛋白分析，证明BIRC2通过与RIPK1结合抑制神经元程序性坏死，为阿尔茨海默病等神经退行性疾病的研究提供依据。
---
如需具体文献，建议通过PubMed或Google Scholar以关键词“BIRC2 antibody”、“cIAP1 antibody”结合研究领域(如癌症、凋亡机制)进一步检索。
**Background of BIRC2 Antibody**
BIRC2 (baculoviral IAP repeat-containing protein 2), also known as cIAP1. is a member of the inhibitor of apoptosis (IAP) protein family, which regulates programmed cell death (apoptosis) and innate immune signaling. BIRC2 contains three conserved baculoviral IAP repeat (BIR) domains that mediate protein-protein interactions and a C-terminal RING domain conferring E3 ubiquitin ligase activity. It primarily inhibits apoptosis by binding to and suppressing caspases, particularly caspase-3 and -7. while also modulating NF-κB signaling pathways through ubiquitination events.
BIRC2 antibodies are essential tools for studying its expression, localization, and function in cellular contexts. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate BIRC2's role in cancer, inflammation, and immune disorders. Dysregulation of BIRC2 is linked to tumor progression, chemotherapy resistance, and autoimmune diseases, making it a potential therapeutic target. For instance, SMAC mimetics, which antagonize BIRC2 and related IAPs, are under exploration in cancer therapy.
Researchers rely on BIRC2-specific antibodies to validate protein interactions, assess post-translational modifications, or evaluate therapeutic responses in preclinical models. Validating antibody specificity is critical, as BIRC2 shares structural homology with other IAPs like BIRC3 (cIAP2). Overall, BIRC2 antibodies are pivotal in unraveling its complex roles in cell survival, death, and disease mechanisms.
×
